Exploring the Market Potential of Braftovi (Encorafenib) and Erbitux (Cetuximab) ± Mektovi (Binimetinib) in Oncology
Overview of the Braftovi + Erbitux ± Mektovi Combination Therapy The combination therapy involving Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has become an important treatment approach for certain cancer types, particularly metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This targeted ther